"We are very pleased to close on the sale of our bioseparations business to KKR" said Kenneth Galbraith, the CEO of Liminal BioSciences. "This transaction significantly strengthens the Company's financial position. We expect that the proceeds to us on closing will extend our cash runway and allow for additional research and development investments in our small molecule therapeutics division."
Subject to the terms and conditions of the share purchase agreement with KKR, the Company is entitled to receive up to an aggregate of GBP 45 million under the transaction. The base purchase price of approximately GBP 29 million was paid at closing of the transaction taking into account certain pre-closing adjustments (the "Closing Payment"). The original upfront payment of GBP 32 million was reduced by GBP2.5 MM to be potentially released to the Company subject to the satisfaction of certain post-closing matters (the "Holdback Amount"), and by GBP 0.5 MM for certain pre-closing adjustments, resulting in a Closing Payment of approximately CAD$ 50 million, subject to certain post-closing adjustments for working capital and indebtedness. In addition to the Closing Payment and the Holdback Amount, Liminal BioSciences will be entitled to receive up to GBP 13 million in deferred milestone payments, which are contingent upon the achievement of future annual PBL revenue thresholds.
As a result of the closing of this transaction, the principal amount available under the non-revolving CAD$75.0 million line of credit available to the Company under the amended loan agreement entered into on November 11, 2019 with the Company's majority shareholder, Structured Alpha LP, was automatically reduced by an amount equal to the net proceeds received by the Company upon the closing of this transaction.
The Company expects to provide additional details regarding the accounting treatment of the gain to be recognized on the sale of PBL as part of its annual report and fourth quarter 2019 financial results.
About Liminal BioSciences Inc.
Liminal BioSciences is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, GPR40, GPR84 and GPR120, known as free fatty acid receptors (FFAR's). These drug candidates have a novel mechanism of action as agonist ("stimulator") of GPR40 and GPR 120, and antagonist ("inhibitor") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alström Syndrome after further consultation and approval by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"). A second drug candidate, PBI-4547, is currently in a Phase 1 clinical study.
Liminal BioSciences has also leveraged its experience in bioseparation technologies through its wholly-owned subsidiary Prometic BioProduction Inc. to isolate and purify biopharmaceuticals from human plasma. Our lead plasma-derived therapeutic product is RyplazimTM (plasminogen) for which the Company expects to file a Biological License Application with the FDA in the first half of 2020 seeking approval to treat patients with congenital plasminogen deficiency.
Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.
Forward Looking Statement
This press release contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, statements with respect to the timing of any planned Biologics License Application filing, timing of initiation of Liminal BioSciences' planned clinical trials, the payment of the Holdback Amount, the achievement of annual PBL revenue threshold and the correlated deferred payments and the provision of details regarding the accounting treatment of the gain to be recognized on the sale of PBL.
These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Liminal BioSciences' ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Liminal BioSciences' to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in the Annual Information Form for the year ended December 31, 2018, under the heading "Risks and Uncertainties related to Liminal BioSciences' Business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
SOURCE Liminal BioSciences Inc.
To read more Press Release articles, click here.